NutriKane D

For 6 years MediKane has been researching and undertaking trials to understand the reasons people taking NutriKane D were seeing lowered blood sugar levels and finding their BSL management to be easier.

How NutriKane D works?
• Lowers blood sugar levels after meals  - independent clinical trial
• Assists in healthy weight loss  - independent weight control study
• NutriKane D is a concentrated food or micro food. It is not a fibre supplement
• Is a safe, natural food. It can be taken with existing medications, and has no side effects
• Contains many micronutrients
• Proven pre-biotic effect

An Australian Innovation
- One of the first foods in the world to receive a patent for use in lowering blood sugar levels and see peer-reviewed publication.
- Australian patent No 21323067 1
- Each claim has been independently tested in Australia, with published clinical trials and scientific research.
Technical Information
The clinical trial on NutriKane D was successful and demonstrated that NutriKane D lowers blood sugar levels after meals.
In detail:
a. Professor Khan observed improvements in the BSL of patients during the previous intestinal health clinical trials on NutriKane. This led to the approval for a specific trial on the benefits of NutriKane D to recuperative care patients living with diabetes.
b.  This trial was a 50 person randomised Clinical Trial (25 control and 25 intervention).
c.  It involved a controlled diet and exercise regimen that eliminated variables.
d. The trial extends 3 month post hospital to assess the ongoing compliance and benefits.
e. This trial was reported as a success in early March 2017 by Professor Khan and her medical team, and the paper is currently being submitted for publication.
Continuing trials:
Royal North Shore Hospital is planning a dietary intervention trial on the benefits of NutriKane D to gestational diabetes and BSL management.
A trial with the Baker IDI is in planning stages to show benefits to people with diabetes over a test meal (a real-world glycemic index (GI)I test specifically using people living with diabetes).
Scientific Evaluations
The underlying mechanisms of the ingredients were analysed in collaboration with researchers at Macquarie University, Sydney, Australia. This work was funded by the Australian government under an Australian Research Council (ARC) grant.
This project has been carried out by 3 PhD candidates with several scientific publications, and found that NutriKane D:
1. Contains high levels of organic and bioavailable micronutrients such as chromium. These nutrients are in a form that can be readily absorbed and used for BSL and metabolism control (unlike artificial supplements)
2. Clear evidence that NutriKane is a multi-level and effective Pre-biotic
a. Feeding the bacteria shown to be beneficial to human health
b. Impeding the growth on bacteria shown to be harmful to human health
c. Promoting the production of Short Chain Fatty Acids (SCFA)
3. NutriKane has direct and indirect anti-inflammatory action (through the microbiota in the gut).
4. High levels of anti-oxidants from several different classes
5. Animal models (mice diabetes model) have shown a protective effect (reduces the incidence and severity of a high fat diet on blood glucose control); an improvement in gut wall health (linked to many conditions such as IBS and IBD) and a more diverse microbiome with lower levels of pro-inflammatory bacteria.
6. This data has been submitted for publication in several peer reviewed journals and is expected to be published mid-2017.

A Weight Control Study was conducted demonstrating significant weight loss for individuals on NutriKane:
1. A dietitian led Weight Loss study was performed that analysed the benefits of NutriKane to a standard weight loss regimen. One hundred (100) individuals were enrolled in an 8 week high level weight loss program that included moderate to high levels of exercise and diet control. Half the group were also given NutriKane as part of their supplementation program but were blinded as to its significance. The study found that the NutriKane group lost almost twice as much weight as the control group over the 8 weeks (5.74kg in the control group compared to 10.19kg in the NutriKane group). NutriKane appeared to be equally beneficial to men and women. Participants also found it easier to maintain the diet control portion of the program. While not specifically tested, it was noted that those people living with diabetes in the trial observed better BSL control during the 8 weeks and had reduced HbA1c at their next check-up.



  1. Mertz W. Chromium occurrence and function in biological systems. Physiol Rev 1969;49:163-239.
  2. Mertz W. Chromium in human nutrition: a review. J Nutr 1993;123:626-33.
  3. Mertz W. Interaction of chromium with insulin: a progress report. Nutr Rev 1998;56:174-7.
  4. Wu, L., Levina, A., Harris, H., Cai, Z., Lai, B., Vogt, S., James, D., Lay, P. (2016). Carcinogenic chromium(VI) compounds formed by intracellular oxidation of chromium(III) dietary supplements by adipocytes. Angewandte Chemie (International Edition), 55(5), 1742-1745.
  5. Huang M, Xie Y, Chen L, Chu K, Wu S, Lu J, Chen X, Wang Y, Lai X. Antidiabetic Mauricio Duarte-Almeida J, Novoa AV, Linares AF, Lajolo FM, Ines Genovese M. Antioxidant activity of phenolics compounds from sugar cane (Saccharum officinarum L.) juice. Plant Foods Hum Nutr. 2006 Dec;61(4):187-92. Epub 2006 Nov
  6. Effect of the Total Polyphenolic Acids Fraction from Salvia miltiorrhiza Bunge in Diabetic Rats. Phytother Res. 2011 Nov 17. doi: 10.1002/ptr.3654.
  7. Klosterbuer A, Roughead ZF, Slavin J. Benefits of dietary fiber in clinical nutrition. Nutr Clin Pract. 2011 Oct;26(5):625-35.
  8. Padayachee, G. Netzel, M. Netzel, L. Day, D. Zabaras, D. Mikkelsen, M.J. Gidley, Binding of polyphenols to plant cell wall analogues – Part 1: Anthocyanins, Food Chemistry, 2012 134(1):155- 161.
  9. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24-38. Review
  11. Sommer P, Sweeney G. Functional and mechanistic integration of infection and the metabolic syndrome. Korean Diabetes J. 2010 Apr;34(2):71-6.
  12. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010 Apr 9;328(5975):228-31.
  13. DeClue AE, Nickell J, Chang CH, Honaker A. Upregulation of proinflammatory cytokine production in response to bacterial pathogen–‐associated molecular patterns in dogs with diabetes mellitus undergoing insulin therapy. J Diabetes Sci Technol. 2012 May 1;6(3):496-502.


Macquarie University - ARC funded ITTC grant:

Professor Nicolle Packer: Director Biomolecular Frontiers Research Centre

Associate professor Mark Molloy: Director Australian Proteomics Analysis Facility, Head of School Macquarie University Department of Chemistry and Biomolecular Sciences

Professor Ian Paulsen: Deputy Director Biomolecular Frontiers Research Centre, 2014 ARC Australian Laureate Fellowship Recipient, listed as one of the world’s 100 most influential minds for 2014 by Thompson Reuters.


      Royal Melbourne Hospital

      Associate Professor Fary Khan

      Associate Professor and Principal Fellow, Department of Medicine, Dentistry and Health Sciences, University of Melbourne & Melbourne Health; Director of the Rehabilitation services and Head of Neurological Rehabilitation Unit, Melbourne Health; and Associate Professor (Research), School of Public Health and Preventative Medicine Monash University. Representative of 9 public hospital networks at the Clinical Leadership Group for the Care of the Older People, Department of Health Victoria; Representative for the Western Pacific Region World Health Organization (WHO), International Classification of Functioning, Disability and Health (ICF) Research Branch; executive member of the WHO International Disaster Committee and Honorary Fellow of the Melbourne EpiCentre and National Ageing and Research Institute; Cochrane Multiple Sclerosis Review group, Psychosocial Influences upon Chronic Disease Outcomes across Europe (PICDOE), University of Leeds; Australasian Faculty of Rehabilitation Medicine; (AFRM); Department of Health; Australian Institute of Health and Welfare (AIHW); Western and Central Melbourne Integrated Cancer Service (WCMICS); World Congress of Rehabilitation Medicine; National Stroke Hospital Network; Australasian Faculty of Rehabilitation Medicine (RACP)

      Dr. Bhaskar Amatya: Project Manager, Department of Rehabilitation Medicine at Royal Melbourne Hospital

      • After the unprecedented benefit observed in improvement to intestinal health outcomes (85-96% improvement on traditional treatments) a new trial specifically targeting diabetes management issues has been started for patients in recuperative care.
      • Patients in long-term hospital stays have difficulty maintaining blood glucose management but also suffer from weight gain and inflammation increase. The current study will measure not just blood glucose management but associated morbidities.
      • The trial will be placebo-controlled randomised and blinded.
      • This trial is being performed as practitioners noticed BGL improvement during the last trials however as it was not a primary outcome of the trial the results cannot be reported.

      Royal North Shore Hospital

      Professor Carol Pollock

      Professor of Medicine, Northern Clinical SchoolKolling Institute of Medical Research; Chairman of the Area Health Advisory Council for the Northern Sydney Central Coast Area Health Service (NSCCAHS), is Research Chairman of the NSCCAHS and Associate Director of the Kolling Institute. She is Chairman of the Greater Metropolitan Task force in NSW (overseeing clinical networks in NSW), and Chairman of the Clinical Variation in Practice subcommittee of the Health Efficiency taskforce. She is a founding director of BioMed North, a company supporting the development of intellectual property out of Area Health Services, and sits on the Board of several philanthropic organizations supporting medical research.

      Dr. Sonia Saad: Senior Research Fellow Medicine, Northern Clinical School

      • After examination of the data collected by MediKane so far Professor Carol Pollock agrees that NutriKane’s current claims are supported by the data collected so far.
      • Her work with diabetes and particularly Chronic Kidney disease has determined that microbiome and short chain fatty acid production is an essential part of treatment and as such has submitted an NHMRC grant for the examination of benefits to individuals living with diabetes. This has the potential to open new markets for the NutriKane brand as well as expanding our current customer base. This application has passed the first round (typical success rate for NHMRC grants is 20-30%)
      • Dr. Sonia Saad also believes that NutriKane should provide benefit for mothers that are at risk of gestational diabetes and two separate grant applications have been submitted, one examining the ability to prevent gestational diabetes and one to examine the ability to treat mothers that already have it. These trials are of particular interest as pregnant mothers are a large market but come at high risk and could not be pursued without a partner such as RNS.
      • Projects that have been proposed for future examination are adolescent-onset type 2 diabetes, obesity and prediabetes treatment and diabetes-related heart disease.